Abstract
Ischaemic heart disease is the leading single cause of death in the US and elsewhere, and a major health problem worldwide.1 The direct cost of hospitalisations for ischaemic heart disease in the US alone is enormous and amounts to more than US$15 billion. Consequently, it is very important to facilitate more definitive ischaemia evaluation while avoiding unnecessary hospital admissions of non-cardiac chest pain patients, as well as avoiding discharge of patients with myocardial infarction (MI).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
